In a bid to blunt criticism of drug pricing, Alnylam Pharmaceuticals (ALNY) is going back to the future. The drug maker plans to limit any future price hikes on a widely anticipated rare-disease drug to the inflation rate, a step that no drug maker has voluntarily embraced in more than two decades.

“As we transition from being an innovative R&D-stage company to a commercial-stage company, we are launching a set of patient access principles,” Alnylam chief executive John Maraganore said. “We plan to grow through innovation, not through price increases. We’ll raise prices to match the Consumer Price Index, and that’s it. And otherwise, we’ll grow, as a company, through innovations.”

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • good to hear. Although, to be honest, once the system is in place RNA therapeutics are dirt cheap to produce. It is indeed one of the many potential theoretical advantages of the technology

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy